• Pacira Pharmaceuticals Inc. reported total revenues for the quarter ended March 31, 2013, were $11.6 million compared with $7.8 million for the quarter ended March 31, 2012. The increase in revenues was primarily driven by $10.4 million of net product sales of Exparel (bupivacaine liposome injectable suspension) in postsurgical analgesia.
Suite: 1100 | Atlanta, Georgia 30346, USA
In the U.S. and Canada: 1-800-477-6307
Outside the U.S.: 1-770-810-3144
In the U.S. and Canada: 1-800-336-4474
Outside the U.S.: 1-215-386-0100
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter